SynthesisBMC urology2014
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
Synthesis in BMC urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis.Current clinical pharmacology · 2019Pooled it
- A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.Prostate cancer and prostatic diseases · 2016Pooled it
- Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy.The journal of sexual medicine · 2014Trial
- Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis.EClinicalMedicine · 2025Article
- Article
- Study of the predictive value of testosterone in androgen deprivation therapy for metastatic hormone-sensitive prostate cancer-the dual clinical research center for western and eastern China.Frontiers in endocrinology · 2025Article
- Review
- Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?Human reproduction open · 2023Review
- Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022Review
- Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.Nature reviews. Urology · 2020Review
- Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.Frontiers in oncology · 2020Review
- Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.Asian journal of urology · 2017Review
- Treatment of Metastatic Prostate Cancer in Older Adults.Current oncology reports · 2016Review
- International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.ESMO open · 2016Article
- Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- EMT, CTCs and CSCs in tumor relapse and drug-resistance.Oncotarget · 2015Review
- Management of metastatic hormone-sensitive prostate cancer.Current urology reports · 2015Review
- Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.Urology annalsReview
- Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.Asian journal of andrologyArticle
- Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Urology annalsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is the most common cancer in older men in the United States (USA) and Western Europe. Androgen deprivation (AD) constitutes, in most cases, the first-line of treatment for these cases. The negative impact of CAD in quality of life, secondary to the adverse events of sustained hormone deprivation, plus the costs of this therapy, motivated the intermittent treatment approach. The objective of this study is to to perform a systematic review and meta-analysis of all randomized controlled trials that compared the efficacy and adverse events profile of intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic hormone-sensitive prostate cancer.
methodsSeveral databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), cancer-specific survival (CSS), time to progression (TTP) and adverse events. We performed a meta-analysis (MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk Ratio (RR), with their corresponding 95% Confidence Intervals (CI 95%).
resultsThe final analysis included 13 trials comprising 6,419 patients with hormone-sensitive prostate cancer. TTP was similar in patients who received intermittent androgen deprivation (IAD) or continuous androgen deprivation (CAD) (fixed effect: HR = 1.04; CI 95% = 0.96 to 1.14; p = 0.3). OS and CSS were also similar in patients treated with IAD or CAD (OS: fixed effect: HR = 1.02; CI 95% = 0.95 to 1.09; p = 0.56 and CSS: fixed effect: HR = 1.06; CI 95% = 0.96 to 1.18; p = 0.26).
conclusionOverall survival was similar between IAD and CAD in patients with locally advanced, recurrent or metastatic hormone-sensitive prostate cancer. Data on CSS are weak and the benefits of IAD on this outcome remain uncertain. Impact in QoL was similar for both groups, however, sexual activity scores were higher and the incidence of hot flushes was lower in patients treated with IAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.